|
|
Article: Antihistamine may arrest cognitive decline in AD.(Neurology)(Alzheimer's disease)(Clinical report)
- Article from:
- Internal Medicine News
- Article date:
- September 15, 2008
- Author:
-
|
Copyright informationCOPYRIGHT 2008 International Medical News Group. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CHICAGO -- An off-the-market antihistamine, previously shown to slow cognitive decline over 1 year in Alzheimer's patients, continued to preserve cognition and memory during a 6-month open-label extension trial.
The drug, dimebon, also stabilized cognition in patients who started on it after taking placebo during the original trial, Dr. Jeffrey Cummings said at the International Conference on Alzheimer's Disease.
"People initially treated with placebo and then crossed over to dimebon did not show the same level of benefit as those people who took dimebon for 18 months after starting the [initial] study," said Dr. Cummings, the Augustus S. Rose Professor of Neurology ...